Background: Since its introduction, palivizumab has been used to prevent respiratory syncytial virus (RSV) infection in high-risk populations. Recommendations for palivizumab administration ...

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...

Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...

Palivizumab is a monoclonal antibody, prescribed for respiratory syncytial virus (RSV) disease in pediatric patients. The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live ...

Hedge-fund powerhouse Two Sigma is likely to pay as much as $100 million to settle a Securities and Exchange Commission investigation into a trading scandal at the firm. The New York firm would ...

NEW YORK - If a swarm of middle schoolers call you an "Alpha Sigma" or a "Looksmax Mogger," take it as a compliment. If they ...

New data from the phase 2/3 MEDLEY trial showed that nirsevimab (formerly MEDI8897) was at least as effective as the older RSV antibody Synagis (palivizumab) in protecting preterm infants or those ...

Learn from anywhere on your own schedule with our 100% online format. Purdue University delivers a best-in-class online Lean Six Sigma (LSS) certificate program for learners with a range of career ...

AstraZeneca Pharma India Limited announced plans to launch Palivizumab (Synagis) in India this October. The company’s stocks were trading at ₹6,730, up by ₹13.75 (0.20 per cent) as of 10.23 ...

That means offering palivizumab – an older, more expensive antibody taken monthly during RSV season – to high-risk infants only, including babies born prematurely or with chronic lung and ...

In spite of a significant reduction in the administration rate of palivizumab between the pre-2014 guideline and post-2014 guideline period, we did not find a significant increase in the RSV ...